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GDF-15 plasma levels in chronic obstructive
pulmonary disease are associated with
subclinical coronary artery disease
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Abstract
Background: Growth differentiation factor-15 (GDF-15), a cytokine associated with cardiovascular mortality,
increases during chronic obstructive pulmonary disease (COPD) exacerbations, but any role in stable COPD is
unknown. We tested associations between GDF-15 and subclinical coronary atherosclerosis, assessed by coronary
artery calcium (CAC) score, in COPD subjects free of clinical cardiovascular disease (CVD).
Methods: Cross-sectional analysis of COPD participants (GOLD stages 2–4) in the COPDGene cohort without CVD at
enrollment, using baseline CAC (from non-EKG-gated chest computed tomography) and plasma GDF-15 (by custom
ELISA). We used multinomial logistic modeling of GDF-15 associations with CAC, adjusting for demographics, baseline
risk (calculated using the HEART: Personal Heart Early Assessment Risk Tool (Budoff et al. 114:1761-1791, 2006) score),
smoking history, measures of airflow obstruction, emphysema and airway disease severity.
Results: Among 694 participants with COPD (47% women, mean age 63.6 years) mean GDF-15 was 1,304 pg/mL, and
mean CAC score was 198. Relative to the lower GDF-15 tertile, higher tertiles showed bivariate association with increasing
CAC score (mid tertile odds ratio [OR] 1.80, 95% confidence interval [CI] 1.29, 2.51; higher tertile OR 2.86, CI 2.04, 4.02). This
association was maintained after additionally adjusting for baseline CVD risk, for co-morbidities and descriptors of COPD
severity and impact, markers of cardiac stress (N-terminal pro–B-type natriuretic peptide, troponin T) and of inflammation
(Interleukin-6), and in subgroup analysis excluding men, diabetics, current smokers or those with limited ambulation.
Conclusions: In ever-smokers with COPD free of clinical CVD, GDF-15 contributes independently to subclinical coronary
atherosclerosis.
Trial registration: ClinicalTrials.gov, NCT00608764. Registered 28 January 2008.
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Background
In chronic obstructive pulmonary disease (COPD), car-
diovascular disease (CVD), especially coronary heart dis-
ease (CHD), is highly prevalent and impacts mortality
and quality of life [1]. COPD is linked to increased risk
of overt CVD by substantial epidemiological data, includ-
ing three large population-based cohorts, two primary care
databases, and the nationally representative NHANES sur-
vey [1–5]. Uniquely among leading causes of death, world-
wide COPD prevalence continues to increase [6, 7],
especially among women [8]. Hence, gains in controlling
CHD mortality may stall unless the independent contribu-
tion from COPD can be combated.
Shared risk factors only partially explain this associ-
ation between COPD and CHD [9, 10]. Its molecular
basis remains undefined, particularly for subclinical dis-
ease, the logical window for prevention. One early CHD
marker is subclinical coronary artery calcium (CAC),
defined as CAC in those free of clinical CVD. CAC is a
validated surrogate measure that predicts future cardio-
vascular events and mortality [11, 12].
Growth-differentiation factor-15 (GDF-15) (gene ID
9518) is a cytokine of the transforming growth factor-β
family associated with endothelial and left ventricular
dysfunction [13]. Elevated GDF-15 is linked to cardio-
vascular and all-cause mortality in older adults [14, 15].
We and others recently identified elevated GDF-15 dur-
ing early COPD exacerbations [16–18].
We hypothesized that in COPD, GDF-15 contributes
significantly to subclinical CHD presence and severity as
determined by CAC, independently of established CVD
risks. We tested this hypothesis using participants with
COPD in a well-characterized cohort who were without
clinical CVD history and >30 days from exacerbation.
Because COPD is heterogeneous [19], with co-morbidity
clustering with specific phenotypes [20, 21], we also ex-
amined associations with imaging-defined phenotypes.
Methods
Study design
This cross-sectional analysis used baseline data from the
Genetic Epidemiology of COPD Study (COPDGene®)
(ClinicalTrials.gov # NCT00608764), an ongoing multi-
center observational cohort designed to identify genetic
factors in smoking-related lung disease [22]. COPDGene
recruited ever-smokers (≥10 pack-year), non-Hispanic
White or African American adults, both sexes, who under-
went a detailed phenotypic evaluation, including high-
resolution chest computed tomography (HRCT).
Ethics, consent and permissions
Studies and consent procedures were performed in ac-
cordance with the Declaration of Helsinki. Participants
understood the study purpose, and provided written
informed consent before any procedures. Protocols were
approved by Institutional Review Boards at VA Ann
Arbor Healthcare System (FWA 00000348) and the Uni-
versity of Michigan (FWA 00004969), approval numbers
2010–120752, HUM000014973, respectively, where we
conducted laboratory and statistical analysis, respectively,
and at all participating clinical sites.
Study participants
Participants were chosen from a biomarker pilot project
(original n = 1000, balanced for sex, age, and equivalent
numbers in GOLD stages 2-4), by selecting subjects with
available CAC scores and without self-reported CVD. We
diagnosed COPD using the fixed-ratio definition [23] (post-
bronchodilator forced expiratory volume in the first second
over forced vital capacity [FEV1/FVC] ratio <0.7, plus
GOLD grade 2–4 obstruction (FEV1% predicted <80%).
Spirometry was performed using an EasyOne™ spirometer
and NHANES III predictions [24]. Participants were CHD-
free on enrollment, based on negative answers to questions
about physician diagnosis (“Have you ever been told by a
physician that you have…”) of heart attack, myocardial in-
farction, coronary artery disease. We also excluded subjects
reporting coronary angioplasty or bypass grafting, con-
gestive heart failure, stroke, transient ischemic attacks
or peripheral vascular disease.
Data collection
Outcome
We scored CAC following Agatston’s algorithm [25, 26],
from HRCT imaging, un-gated for EKG, and stratified
into categories of 0, 1–100, 101–400 and >400 Agatston
Units (absence of CAC, mild/minimal, moderate and ex-
tensive plaque burden, respectively) [27]. The accuracy
and reliability of CAC scoring using un-gated HRCT has
been validated in comparisons with EKG-gated studies
in COPDGene participants [28].
Exposure
We measured GDF-15 levels by ELISA according to man-
ufacturer’s instructions from plasma collected at enroll-
ment and stored at -80 °C until analyzed in duplicate;
values are presented in pg/mL; the lower limit of detection
is 2 pg/mL.
Covariates
Demographics, smoking and medical history were collected
using self-administered questionnaires. Co-morbidities and
risk factors were ascertained by combining responses to
questions on physician-based diagnosis and review of
current medications. We considered hypertension, hyper-
lipidemia and diabetes present when the participant re-
ported either diagnosis or current medication use for that
disease. Physical activity was considered limited based on
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affirming “Was your walk limited?” during a 6-min walk
test. We calculated 10-year CHD risk based on Personal
Heart Early Assessment Risk Tool (HEART score) [25], a
validated assessment based on self-reported data [29] suit-
able for use in subjects without previous CHD diagnosis
and in the public domain.
We obtained emphysema percentage and airway wall
thickness from volumetric HRCTs obtained at full infla-
tion [22], using 3D Slicer software (www.Slicer.org) and a
VIDA Pulmonary Workstation, respectively. Lung areas
< -950 Hounsfield Units were considered emphysema,
which we stratified as below or ≥10% of lung volume. Air-
way metrics included the square root of the wall area of a
theoretical airway of 10 mm luminal perimeter (Pi10).
Additional plasma analytes
We measured troponin T, N-terminal-proBNP and IL-6 on
the same samples using Luminex assays from Milliplex
MAP Human Cardiovascular Disease Panels (EMD
Millipore, Billerica, Massachusetts). Assays were run
in duplicate according to manufacturer's instructions.
The lower limits of detection were 9 pg/mL, 18.8 pg/mL
and 0.2 pg/mL, respectively.
Statistical analysis
Demographics, smoking history, lung function and cardio-
vascular risk were analyzed by GDF-15 tertiles, using t-test
or chi-square. We tested association between GDF-15 ter-
tiles and CAC burden categories by two strategies. First,
we used regression models with CAC as outcome. Second,
we developed sequential multinomial logistic regression
models including variables grouped in bloc, starting with
GDF tertiles, then adjusting for baseline HEART score,
then further adjusting for co-morbidities, measures of
lung function, and severity of airway disease and emphy-
sema. We selected logistic modeling as our main approach
because it presents outcome and exposure as categories,
rather than numeric values, improving their interpret-
ability and clinical relevance. We tested interactions of
GDF-15 with imaging characteristics and lung function
using similar models. Analyses were performed using
Prism 6.0f (GraphPad Software, Inc; La Jolla, CA) and
Stata v.12 (College Station, TX).
Results
We included 694 subjects free of clinical CVD, with large
proportions of women and those with chronic bronchitis
and >50 pack-years smoking history (Table 1). Almost half
were considered at low cardiovascular risk (10 year CHD
risk <10%) by HEART score. As a group, men had sig-
nificantly higher CAC scores (p < 0.0001) (Fig. 1a) and
GDF-15 levels (p = 0.007) (Fig. 1b).
As anticipated, there was a correlation between
GDF-15 levels and log2CAC that was modest (rS = 0.2693;
R2 = 0.05982) but significant (p < 0.0001) (Fig. 2). Neither
CAC nor GDF-15 correlated with pulmonary artery en-
largement, as determined by the ratio of pulmonary artery
and aorta diameters (PA:A ratio) [30] (Additional file 1:
Table S1), implying that this association did not reflect oc-
cult pulmonary hypertension.
Comparing participants by GDF-15 tertiles, those in
the higher tertile were significantly older, and more often
men and non-Hispanic whites (Table 1). Additionally,
high GDF-15 tertile participants had greater smoking
histories, more frequently had diabetes, hypertension,
hyperlipidemia and obesity, and were more frequently
classified at intermediate or high risk by HEART score.
However, there were no differences in measures of lung
function, dyspnea or emphysema severity (Table 1).
In bivariate and multivariate analyses, GDF-15 levels
(in tertiles) were associated with higher CHD risk by
HEART score and by its components, including age,
smoking and diabetes (Additional file 1: Table S2). Again,
however, GDF-15 levels were not influenced by common
descriptors of COPD severity (GOLD spirometry severity,
FEV1, exacerbation history) or phenotypes (chronic
bronchitis, measures of emphysema or airway thickness)
(Additional file 1: Table S2).
With increasing GDF-15 tertiles, median CAC scores
rose, both as absolute values (not shown) and after loga-
rithmic transformation (Fig. 3). There was a stepped in-
crease in CAC scores with increasing GDF-15: relative
to the lower GDF-15 tertile, we found 1.19-fold and
2.10-fold increases, respectively, in mid- and highest ter-
tiles. Nevertheless, even in the highest tertile, not all
subjects had measurable CAC (Fig. 3).
In logistic models, GDF-15 contributed significantly to
CAC burden (Table 2). The association of GDF-15 and
CAC (by severity groups) was strong in the bivariate
model (Model 1), and remained of similar magnitude
after additionally adjusting for baseline cardiovascular
risk (Model 2), for co-morbidities and measures of lung
function (Model 3), and for biomarkers (Model 4). Im-
portantly, the magnitude of the GDF-15-CAC associ-
ation was at least as great as that of the combined
classical risk factors included in the HEART score.
Next, we performed a sensitivity analysis, testing the as-
sociation in subgroups chosen to minimize known correl-
ation with CAC. First, we restricted analysis to women
(Table 3). Second, we excluded those with diabetes, a major
contributor to the HEART score that is associated with
both CAC and GDF-15 elevation. Third, we restricted ana-
lysis to those not smoking at enrollment. Fourth, because
low physical activity and a sedentary lifestyle are strong
CVD risk factors, we repeated the analysis using only those
reporting no walking limitations. None of these pre-
planned subgroups analysis significantly modified the asso-
ciation of GDF-15 (higher tertile) with CAC (Table 3).
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Finally, we tested whether different markers of COPD
phenotype and severity modified this association (Additional
file 1: Table S3). Given correlations between airway thickness
and cardiometabolic diseases [21], we used two approaches,
restricting the analysis to those with less airway disease
(lower two tertiles of pi10 distribution) or those with
greater emphysema. We also restricted analysis to sub-
jects with less severe airflow obstruction (defined
either as spirometry stage 2–3 or FEV1 ≥ 1 L). None of
these analyses (Additional file 1: Table S3) changed the
associations between GDF-15 and CAC.
Discussion
This analysis of 694 ever-smokers without clinical CVD
at enrollment to the COPDGene cohort demonstrates
that GDF-15 independently contributes to subclinical
Table 1 Characteristics of COPDGene participants with COPD, by GDF-15 tertiles
All participants
(n = 694)
Lower (≤966 pg/mL)
(n = 231)
Mid (967-1438 pg/mL)
(n = 232)
Higher (≥1439 pg/mL)
(n = 231)
p-value
Sociodemographics
Age (mean, s.d.) 63.6 (8.4) 59.7 (7.4) 64.6 (8.1) 66.4 (8.3) <0.001
Females (%) 47.1 49.4 52.6 39.4 0.01
African American (%) 16.3 21.7 13.8 13.4 0.02
BMI (mean, s.d.) 27.3 (6.0) 27.5 (6.0) 26.8 (5.7) 27.6 (6.2) 0.31
Respiratory status
FEV1 in L (mean, s.d.) 1.25 (0.64) 1.28 (0.69) 1.20 (0.61) 1.26 (0.60) 0.30
FEV1 % predicted (mean, s.d.) 43.5 (18.8) 42.9 (19.3) 42.9 (18.6) 44.7 (18.4) 0.50
FEV1/FVC % (mean, s.d.) 44.4 (13.6) 44.2 (13.8) 43.9 (13.5) 45.4 (13.6) 0.45
GOLD stage (%)
II 34.1 31.6 33.2 37.7
III 33.6 32.9 35.8 32.0
IV 32.3 35.5 31.0 30.3 0.55
mMRC dyspnea score (mean, s.d.) 2.3 (1.4) 2.3 (1.4) 2.2 (1.4) 2.3 (1.4) 0.48
Pack-years smoked (mean, s.d.) 52.2 (25.3) 47.8 (23.6) 52.0 (24.2) 56.8 (27.3) <0.001
Six-minute walking distance, in f. (mean, s.d.) 1163 (395) 1221 (395) 1180 (377) 1087 (403) 0.001
Chronic bronchitis (%) 27.0 26.4 26.7 27.7 0.94
Emphysema % (mean, s.d.) 17.1 (14.4) 18.2 (14.7) 17.1 (14.2) 16.0 (14.2) 0.26
Pi10 (mean, s.d.) 3.73 (0.14) 3.72 (0.14) 3.71 (0.13) 3.75 (0.14) 0.04
Cardiovascular risk factors (%)
BMI ≥30 29.0 28.1 26.3 32.5 0.32
Diabetes 8.7 2.6 4.7 18.6 <0.001
Currently smoking 29.8 31.6 25.0 32.9 0.13
Hypertension 43.8 34.6 46.1 50.7 0.002
Hyperlipidemia 36.6 28.1 41.0 40.7 0.005
Aggregate 10-year coronary heart disease riska (%)
Low (<10%) 44.5 56.3 47.0 30.3
Intermediate (10%–20%) 39.9 37.7 38.8 43.3
High (>20%) 15.6 6.1 14.2 26.4 <0.001
Other co-morbidities (%)
GERD 28.4 30.3 28.0 26.8 0.70
Asthma 22.5 26.4 22.8 18.2 0.10
Osteoporosis 15.9 13.4 17.2 16.9 0.46
Osteoarthritis 15.0 13.0 13.8 18.2 0.24
Stomach ulcers 8.4 10.4 8.2 6.5 0.31
aBased on the HEART score, as described in the Methods section
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atherosclerosis in COPD. Although GDF-15 is elevated
in pulmonary hypertension of any cause, we found no
correlation with PA:A ratio. The association of GDF-15
with CAC showed a gradient, and both its magnitude,
and its persistence in subgroup analyses, imply that
GDF-15 is not simply a surrogate for traditional risk fac-
tors. Instead, our findings support the concept [31] that
adding GDF-15 to established indicators improves CVD
risk estimation. This supposition, which will require add-
itional testing, is most relevant to younger COPD sub-
jects in low GOLD stages, in whom long-term CVD risk
could exceed that of respiratory death. Thus, these data
have important implications for reducing the impact of
multi-morbidity in ever-smokers and also provide poten-
tial mechanistic insight into the link between COPD and
overt CVD [1–5].
Reduced lung function as powerfully predicts CVD
mortality as total cholesterol [32] but has never been
embraced as a modifiable risk factor. Our findings are
consistent with reported associations between smoking,
airflow limitation and subclinical atherosclerosis, as
measured by carotid intimal thickening [33]. We extend
those results by using CAC score, which has higher pre-
dictive value for incident CVD than carotid plaque [34],
and by showing independence from active smoking.
That point is important, as GDF-15 is elevated by smok-
ing [3] and cigarette smoke induces its production by
human lung epithelial cells in vitro [35].
We extend to stable COPD without clinical CVD the
evidence that GDF-15 is an informative biomarker, as
established in overt CVD [36, 37]. To our knowledge,
the only previous study that analyzed GDF-15 in stable
COPD [38] found elevated levels relative to healthy
never-smokers, but was underpowered (n = 15) to exam-
ine other correlations. Our findings agree with two large
(combined n = 2395) studies of community-dwelling eld-
erly individuals without CVD history in showing that
GDF-15 adds significant value to predictive models
based on accepted CVD biomarkers [14, 15]. Those longi-
tudinal studies additionally found that baseline GDF-15
levels independently predicted all-cause and cardiovas-
cular mortality [14, 39], which we hope to examine in
our 694 COPDGene participants. Importantly, associa-
tions of GDF-15 with mortality in the general popula-
tion equal or exceed that of N-terminal pro-BNP and
C-reactive protein [14, 15].
However, the clinical value of CAC is debated, and
currently only recommended for selected asymptomatic
adults at intermediate risk [40]. Data on CAC in COPD
are conflicting. A single-center case-control study (n = 162)
found no difference in CAC despite higher major adverse
cardiovascular events in COPD [41]. By contrast, CAC on
non-EKG-gated CTs correlated significantly with all-cause
mortality in ECLIPSE, in an analysis including those with
known CVD [27]. Interestingly, CAC scores in ECLIPSE
did not correlate with FEV1 or exacerbation history.
Similarly, we did not find a correlation of baseline
GDF-15 levels and common markers of COPD severity
Fig. 1 CAC scores & GDF-15 plasma levels by sex. CAC scores were de-
termined by analysis of non-EKG-gated HRCT and GDF-15 plasma
levels were measured by ELISA. a, CAC scores, as Agatston Units; b,
GDF-15 concentrations, as pg/mL. Data are median (bar), 25th &
75th percentiles (box), 5th & 95th percentiles (whiskers) with out-
liers shown as individual points. p-values by Mann-Whitney test
Fig. 2 Correlation between Log2 CAC & GDF-15 plasma concentrations.
p-value by Spearman correlation (rS), goodness of fit (R
2) by linear
regression (n = 694)
Fig. 3 Distribution of Log2 CAC by GDF-15 tertiles. Lower tertile
(<966 pg/mL) (n = 231), mid tertile (967-1438 pg/mL) (n = 232),
higher tertile (>1439 pg/mL) (n = 231)
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and phenotypes. Thus, GDF-15 appears to be a prognostic
biomarker of CVD co-morbidity, but not a predictive bio-
marker of COPD outcomes, in agreement with recent
findings suggesting that endothelial dysfunction predicts
atherosclerosis in COPD, but does not contribute to air-
flow limitation [42].
As a biomarker, GDF-15 has both strengths and limita-
tions. Although GDF-15 appears to reflect an integrated
stress response [15, 37], understanding the significance of
an elevated concentration is complicated by its production
by multiple cell-types and in response to disparate stimuli
[43]. Elevated GDF-15 may reflect endothelial cell dys-
function, common in advanced COPD and proposed as a
shared pathway in CVD development [44]. However, endo-
thelial dysfunction in COPD appears to relate in part to in-
trathoracic mechanics rather than inflammation [45], and
may associate with specific COPD phenotypes [46]. Hence,
GDF-15 might be elevated in individual COPD patients for
diverse reasons. Thus, like TGF-β itself, GDF-15 may not
be simply good or bad, but either, depending on context,
underlining the need for greater understanding of its signal
transduction in specific cell-types and clinical settings.
Despite the strengths of a well-characterized cohort in
which the CAC outcome has been validated [28], potential
limitations include information bias, as coexistent diseases
were self-reported. Although a significant concern for in-
cident diseases, information bias is less so for prevalent
diseases [47]. We attempted to improve the accuracy of
excluding baseline CVD by supplementing self-reported
diagnoses with history of related treatment or interven-
tions. A second potential limitation is our use of a self-re-
ported risk score to calculate future CHD likelihood,
instead of biologic measures included in some common
predictive instruments. However, the HEART score is a
validated instrument specifically designed to use self-
reported data in epidemiologic studies [29]. Finally, our
cross-sectional design limits inferences about temporal
associations. Nevertheless, we consider our findings robust,
consistent with current understanding of associations be-
tween CHD and COPD and an advance in understanding
the mechanisms involved in both diseases.
Conclusions
We demonstrate that in COPD subjects free of clinical
CVD, subclinical atherosclerosis (measured as CAC on
ungated HRCT) is frequent; and that GDF-15 contributes,
independently of common cardiovascular risk factors and
Table 2 Adjusted associations of GDF-15 levels and of cardiovascular risk with CAC score among COPDGene participants with COPD
(n = 694)
Model 1a Model 2b Model 3c Model 4d
GDF-15 level (in tertiles)
Lower tertile Ref. Ref. Ref. Ref.
Intermediate tertile 2.52 (1.10, 2.71) 2.30 (1.19, 4.44) 2.16 (1.11, 4.20) 1.87 (0.88, 3.99)
Higher tertile 5.70 (3.08, 10.56) 4.53 (2.40, 8.54) 4.22 (2.20, 8.07) 4.28 (2.09, 8.76)
Coronary heart disease risk groupe
Low (<10%) Ref. Ref. Ref.
Intermediate (10%-20%) 1.49 (0.86, 2.57) 1.46 (0.83, 2.58) 1.33 (0.69, 2.55)
High (>20%) 2.89 (1.45, 5.77) 3.77 (1.79, 7.94) 3.97 (1.68, 9.35)
All entries represent risk ratio of being in the higher group of CAC and its 95% CI, based on multinomial logistic regression models, in which GDF-15 tertiles are
compared again the lower tertile as reference, and the groups of cardiovascular risk by the HEART score are compared with the low-risk group as reference.
aModel 1: Bivariate. bModel 2: Model 1 additionally adjusted for baseline coronary heart disease risk group. cModel 3: Model 2 additionally adjusted for race,
GOLD spirometry stage, pack-years smoked, chronic bronchitis symptoms, history of exacerbations, measures of emphysema and airway thickness, and co-
morbidities (asthma, GERD, mobility-related diseases). dModel 4: Model 3 additionally adjusted for N-terminal pro–B-type natriuretic peptide, troponin T and
Interleukin-6. eBased on the HEART score, as described in the Methods section
Table 3 Multivariate models of association of GDF-15 with CAC score among different subgroups of COPDGene participants with COPD
Restricted to
Female participants
(n = 327)
Participants without
diabetes (n = 634)
Participants not currently
smoking (n = 487)
Participants with no walking
limitation (n = 304)
GDF-15 level (in tertiles)
Lower tertile Ref. Ref. Ref. Ref.
Intermediate tertile 2.36 (0.84, 6.64) 1.95 (0.99, 3.84) 1.40 (0.66, 2.98) 1.48 (0.57, 3.87)
Higher tertile 4.56 (1.62, 12.8) 4.00 (2.06, 7.78) 2.41 (1.13, 5.12) 3.76 (1.63, 10.4)
All entries represent risk ratio of being in the higher group of CAC and its 95% CI, based on multinomial logistic regression models
All models additionally adjusted for race, GOLD spirometry stage, pack-years smoked, chronic bronchitis symptoms, history of exacerbations, and co-morbidities
(asthma, GERD, mobility-related diseases)
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measures of COPD severity or phenotype, to its presence
and severity.
Additional file
Additional file 1: Tables S1-S3. Table S1. Lack of association of
GDF-15 levels or CAC score with PA:A ratio*. Table S2. Bivariate and
Multivariate Associations with GDF-15 among COPDGene participants with
COPD (n= 694). Table S3. Multivariate models of association of GDF-15 with
CAC score among different subgroups of COPDGene participants with COPD.
(DOCX 33 kb)
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